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LETTERS TO THE EDITOR
Regarding “Replanting the inferior mesenteric artery
during infrarenal aortic aneurysm repair: influence on
postoperative colon ischemia”
I hoped to find good level 1 evidence in the first randomized
trial on the influence of replanting the inferior mesenteric artery
(IMA) or ligation during open (semi)elective AAA repair on post-
operative colon ischemia in the study by Senekowitsch et al (J Vasc
Surg 2006;43:689-94). However, after having read the article, I
still don’t have an answer.
The primary end point in this trial was colon ischemia assessed
with sigmoidoscopy, and the secondary end point was mortality.
Although the authors acknowledge that the study was underpow-
ered to detect a significant difference in ischemic colitis, it might be
that the study design and analysis also contributed to this result.
An intention-to-treat analysis shows no differences in ischemic
colitis and mortality in both study groups (Table II). Then the
authors jump to a subgroup analysis. Of the 71 patients assigned to
IMA replanting, only 42 had a patent IMA, and patency in 25 of
the remaining 29 patients could be restored by thrombectomy or
endarterectomy. In 25 of the 86 patients assigned to ligation, the
IMA was occluded. These patients were excluded from a detailed
analysis of ischemic colitis. Thus, the authors actually compare an
attempt to optimize circulation of the colon in 67 patients vs
maximum compromise of this circulation in 61 patients. Yet, no
differences could be established in the incidence of ischemic colitis
or mortality. In addition, data on the extent of ischemic colitis in
five of nine asymptomatic patients are not provided in the results.
Finally, the authors try to identify risk factors for ischemic
colitis in the cohort of 128 (and not the original 157) patients by
calculating relative risks for different factors. Although the risks are
properly calculated, they are not correctly summarized in Table V.
A post hocmultivariate analysis could also have helped identify
independent predictors of ischemic colitis or mortality. The au-
thors suggest that older patients with increased operative blood
loss might benefit from IMA replantation because this procedure
does no harm. This advice is not supported by the data in this
interesting study.
Mark Koelemay, MD, PhD
Department of Surgery
Ziekenhuis Hilversum
The Netherlands
doi:10.1016/j.jvs.2006.05.059
Reply
We thank Dr Koelemay for his interest in our article and also
for pointing out some relevant aspects of our study.
Assessing the primary cause of ischemic colitis after aortic
reconstructions is, as you also pointed out, not always an easy task,
as it is multifactorial in origin. We tried to minimize potential
confounders by excluding all patients but those with at least one
patent hypogastric artery and without chronic colon disease or
previous colon resection. Also, clinically relevant ischemic colitis is
relatively rare, and differences between groups were (as demon-
strated in the past) not large. Therefore, histology was our only
possible end point, arguably not always clinically relevant, yet—as
we believe—most sensitive for the purpose of the study.
It is correct that the intention-to-treat analysis as well as the
analysis of the subgroup with patent inferior mesenteric artery
(IMA) did not yield significant differences between the groups.
The reason for mainly discussing the subgroup with patent IMA is
also quite apparent: An already occluded vessel cannot have any
influence on outcome if ligated or not.We initially encompassed all
patients into the analysis; however, it was an explicit demand by the
reviewers and editors of the Journal of Vascular Surgery to mainly
include patients with a patent IMA, and we do fully agree that the
later patients are the relevant ones for final evaluation. A multivar-
iate analysis was also performed but did not yield further insight
into causes for postoperative ischemic colitis.
When analyzing all 157 patients regarding risk factors, no
different results were seen: age, sex and blood loss were the
parameters differing between patients with and without ischemic
colitis. We believe that this result is actually of great relevance as it
demonstrates that we are mainly talking about a hemodynamic
problem in open surgery and not—as frequently believed—an
embolic one, also underlined by the occurrence of ischemic colitis
in patients with an occluded IMA. Histologic results of all patients
are listed in the first paragraph of the “Results” section.
Finally, we do agree that our data do not fully support the
suggestion to replant the IMA in older patients and in those with
high intraoperative blood loss. Yet, the fact that we did not
encounter a single complication, neither intraoperatively nor post-
operatively, by replanting the IMA and that revascularization
usually means increased perfusion pressure and thus optimizing
critical flow justifies the suggestion. Even more so, as we could not
produce final evidence against IMA replant in patients with at least
one patent hypogastric artery, even though it did not prove to be
beneficial in the whole study population or the subgroup of
patients with patent IMA.
Afshin Assadian, MD
Department of General and Vascular Surgery
Wilhelminenspital
Vienna, Austria
Ojan Assadian, MD, DTM&H (Lond)
Clinical Institute for Hygiene and Medical Microbiology
Medical University Vienna
Vienna, Austria
doi:10.1016/j.jvs.2006.06.017
Regarding “Diffuse phlegmonous phlebitis after
endovenous laser treatment of the great saphenous
vein”
We read the case report by Dunst and colleagues (J Vasc Surg
2006;43:1056-8) with much interest. Tens of thousand cases of
endovenous laser ablation (EVL) have been done with no infection
reported.1,2 Therefore, one may suspect that appropriate guide-
lines for performing EVL were not followed.3-5 These deviations
may have contributed to this serious infection.
1. The entry point of the laser (presumably percutaneous) was too
close to the ulcer, ie, 10 cm; moreover, it appears that another
incision was made between the entry point and ulcer to ligate
perforators.
2. No tumescent anesthesia was used.
3. Prophylactic antibiotic was not used, in the presence of an active
ulcer, where additional procedures were performed.
We recently published our results of the first 1250 EVLs,2
among which were 52 patients with active ulcers. All the cases were
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done under only tumescence anesthesia, and no additional proce-
dures were done concomitantly. There were no infections, and
over 75% of ulcers healed within 2 weeks.
We have discussed the importance of tumescence anesthesia in
EVL previously.4 Besides collapsing the vein, tumescence also
protects the surrounding structures from the intense heat pro-
duced by the laser. Necrotic tissue will add to the chance of serious
infection.
The reported incidence of infection with subfascial endoscopic
perforator vein surgery (SEPS) is from 0% to 14%.6,7 The infection
reported by Dunst et al should be compared with SEPS and not
with EVL because additional procedures were done in an active-
ulcer patient.
We agree with the author’s conclusion that EVL is a reliable
and efficient technique; however, we disagree with performing
additional procedures besides EVL in patients with active ulcer.
Rajagopalan Ravi, MD
Edward B. Diethrich, MD
Arizona Heart Institute Vein Center
Phoenix, Ariz
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Reply
We thank Drs Ravi and Diethrich for their interest and their
comments on our article “Diffuse phlegmonous phlebitis after
endovenous laser treatment of the great saphenous vein” (J Vasc
Surg 2006;43:1056-8) and the opportunity to reply. We admire
their vast experience with endovenous laser ablations, and, there-
fore, their recommendations are warrantable. Despite some possi-
ble shortcomings, such as waiving of perioperative antibiotics, we
still believe that we treated this patient in the best possible manner.
In fact, the intention to publish this case was mainly to show that
aggressive treatment may sometimes be necessary even after so-
called minor surgical procedures, such as endovenous laser treat-
ment.
However, we are grateful to Drs Ravi and Diethrich for their
recommendations and will incorporate them in our future treat-
ment regimens.
Karin M. Dunst, MD
Georg M. Huemer, MD
Wolfgang Wayand, MD
Andreas Shamiyeh, MD
Allgemeines Krankenhaus Linz
Linz, Austria
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